Job Cuts at Rosetta Inpharmatics, Inc.
As part of a consolidation of its oncology research operations, Merck & Co. is eliminating 12 positions at its Seattle-based subsidiary, Rosetta Inpharmatics. The reorganization will affect only a small fraction of Rosetta's 350 employees, and the site's overall head count will not change, a Merck spokeswoman said.